Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sigyn Therapeutics ( (SIGY) ) has issued an update.
On August 8, 2025, Sigyn Therapeutics, Inc. entered into a Convertible Note Purchase Agreement with Lambda Venture Partners, LLC, allowing the issuance of up to $550,000 in convertible promissory notes. The first tranche of $110,000 was issued on August 11, 2025, with proceeds of $100,000. Additionally, the company faced significant changes in its Board of Directors, with resignations from Richa Nand, Michael Ryan, and Christopher Wetzel due to the discontinuation of directors’ and officers’ liability insurance, which expired on August 4, 2025.
Spark’s Take on SIGY Stock
According to Spark, TipRanks’ AI Analyst, SIGY is a Underperform.
The overall score reflects significant financial challenges, including persistent net losses, high leverage, and no revenue growth. Technical indicators show mixed signals, with potential short-term upward momentum but risk of being overbought. The valuation is concerning with a negative P/E ratio, suggesting the stock is not a value play. The lack of clear communication in the earnings call adds to the uncertainty. Overall, the stock presents high risk with limited visibility into future improvements.
To see Spark’s full report on SIGY stock, click here.
More about Sigyn Therapeutics
Average Trading Volume: 1,007
Technical Sentiment Signal: Sell
Current Market Cap: $4.5M
See more data about SIGY stock on TipRanks’ Stock Analysis page.